Metagenomi Inc (MGX) concluded trading on Wednesday at a closing price of $3.03, with 16.9 million shares of worth about $51.21 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -32.21% during that period and on January 22, 2025 the price saw a gain of about 11.40%. Currently the company’s common shares owned by public are about 37.43M shares, out of which, 18.78M shares are available for trading.
Stock saw a price change of 9.78% in past 5 days and over the past one month there was a price change of -2.57%. Over the period of past 52 weeks, stock dropped to lowest price of $1.61 but also hit the highest price of $12.74 during that period. The average intraday trading volume for Metagenomi Inc shares is 2.05 million. The stock is currently trading -9.31% below its 20-day simple moving average (SMA20), while that difference is up 7.87% for SMA50 and it goes to -24.97% lower than SMA200.
Metagenomi Inc (NASDAQ: MGX) currently have 37.43M outstanding shares and institutions hold larger chunk of about 24.96% of that.
The stock has a current market capitalization of $113.39M. It has posted earnings per share of -$2.50 in the same period. It has Quick Ratio of 6.18 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MGX, volatility over the week remained 12.73% while standing at 11.98% over the month.
Stock’s fiscal year EPS is expected to rise by 87.64% while it is estimated to decrease by -7.39% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on May 07, 2024 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by JP Morgan stated Metagenomi Inc (MGX) stock as a Neutral in their note to investors on May 02, 2024, suggesting a price target of $6 for the stock. Stock get an Overweight rating from JP Morgan on March 05, 2024.